Date: 2017-07-18
Type of information: Licensing agreement
Compound: inhibitor of the Kv1.3 ion channel
Company: 4SC (Germany) Maruho (Japan)
Therapeutic area: Autoimmune diseases - Dermatological diseases
Type agreement: licensing
Action mechanism: ion channel inhibitor/Kv1.3 inhibitor. Kv1.3 is a voltage-gated ion channel which has diverse functions in various cell types and cellular mechanisms but plays an essential role in the activation and proliferation of T cells. 4SC's inhibitors of the Kv1.3 ion channel are designed to spare "normal" immune cells but to act on chronically stimulated cell populations thus addressing an underlying pathogenic principle in a multitude of autoimmune diseases.
Disease:
Details: • On July 18, 2017, 4SC has granted an exclusive worldwide license to Maruho on a preclinical compound class inhibiting the ion channel Kv1.3. Summit Pharmaceuticals International, a subsidiary of Sumitomo Corporation, served as advisor to 4SC in connection with this transaction.
Financial terms: Under the licensing agreement, 4SC will be eligible to receive upfront and milestone payments totaling up to € 103 million, plus commercial milestones totaling up to an additional € 105 million and single-digit royalties on commercial sales.
Latest news:
